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420a Tuesday, March 8, 2011receptor aggregates that represent the functional signaling complex. Here, using
a combination of receptor mutagenesis, experiments in living cells (including
FRET), and experiments with purified peptides we report receptor oligomeriza-
tion driven through both covalent and non-covalent interactions in membrane-
proximal regions of the receptor. These results represent the first findings that
pre-ligand receptor oligomerization and signal propagation into the cell may
be driven in part through receptor interactions within and near the membrane.
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A Similar Motif Shared by HIV-1 gp41 and TCRA Trans-Membrane Do-
mains Exploited by the HIV Virus to Modulate T-Cell Proliferation
Yechiel Shai, Tomer Cohen, Shmuel Jaffe Cohen, Niv Antonovsky,
Irun R. Cohen.
The transmembrane domains (TMDs) of the T-cell receptor (TCR) play an im-
portant role in the assembly of the receptor complex. Previous studies have
shown that the fusion peptide (FP) of HIV-1 inhibits T-cell activation and by
that suppress the immune response against the virus. FP gains this activity by
specifically binding to the TMD of TCRa and interfering with the assembly
of the TCR complex We utilized in-silico testing of a TMD sequence library
derived from virus protein sequences, and pin-pointed a nine amino-acid motif
shared by a group of different viruses; this motif resembles the transmembrane
domain of the a-subunit of the T-cell receptor (TCRa). The highest similarity
was found within SIV and HIV glycoprotein 41 TMD (gp41 TMD). Previous
studies have shown that stable interactions between TCRa and CD3 are local-
ized to this nine amino acid motif within TCRa, and a peptide derived from it
interfered and intervened in the TCR function when added exogenously. By
combining biophysical and biochemical approaches we found that the gp41
TMD peptide co-localizes with CD3 within the TCR complex and inhibits
T-cell proliferation in vitro. We also found that the inhibitory mechanism of
gp41 TMD differs from that of FP. Disassociated from HIV, the gp41 TMD
molecule provides a novel mechanism for down regulating undesirable re-
sponses and might be be used as an immunotherapeutic tool.
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Cooperativity in the Binding of Agonists to Reconstituted Tetramers of the
M2 Muscarinic Receptor
Dar’ya S. Redka, Heiko Heerklotz, James W. Wells.
G protein-coupled receptors display a dispersion of affinities in the binding of
agonists, the breadth of which is a measure of efficacy. The implied heteroge-
neity commonly is thought to be induced by the G protein in an otherwise ho-
mogeneous population of receptors. In some early studies, however, purified
M2 muscarinic receptor also revealed heterogeneity under some conditions.
We have shown that M2 receptors extracted from Sf9 cells can be purified as
monomers devoid of G protein and reconstituted almost exclusively as tetra-
mers in phospholipid vesicles (POPC/POPS/cholesterol), as indicated by
cross-linking. Monomers in solution appeared homogeneous, as indicated by
Hill coefficients near 1 for the inhibitory effect of agonists on binding of the
antagonist N-[3H]methylscopolamine; in contrast, reconstituted tetramers ap-
peared heterogeneous (nH < 1) in a manner that correlated with efficacy as re-
ported for GTPase activity (p = 0.013). It follows that efficacy is intrinsic to the
receptor in its tetrameric state.
To examine whether heterogeneity arises from pre-existing asymmetry within
the tetramer or is induced through cooperativity between ligands, the inhibitory
effect of two agonists (oxotremorine-M, arecoline) and two antagonists (N-
methylscopolamine, atropine) was measured at two concentrations of N-[3H]
methylscopolamine. The data were analyzed simultaneously in terms of four
dissimilar and non-interacting sites (i.e., asymmetry) and four interacting sites
(i.e., cooperativity). The radioligand was assumed to label only two of the four
sites, because the capacity for N-[3H]methylscopolamine doubled upon disso-
lution of reconstituted receptors in digitonin; one-half of the reconstituted sites
therefore were inaccessible to the radioligand. Whereas the data could not be
described in terms intrinsic asymmetry alone, the fit improved markedly
upon the introduction of cooperative interactions (p< 0.00001). Efficacy there-
fore appears to arise at least in part from cooperativity within the tetramer.
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Mechanistic Insights into Reversal of Pulmonary Hypertension by Estro-
gen Therapy
Soban Umar, Humann Matori, Andrea Iorga, Michelle Afkhami,
Jingyuan Li, Federica Maltese, Mansoureh Eghbali.
Severe pulmonary hypertension(PH) leads to right-ventricular failure(RVF) and
death. Estrogen(E2) pretreatment has been shown to attenuate development of
PH. Here, we tested the hypothesis that E2 may also reverse advanced PH and
investigated its underlyingmechanisms.Male rats were treated withmonocrota-
line(MCT,60 mg/kg) to induce PH(n=36). At day-21 when PH had established,
one group was euthanized(PH, n=8), and 5 other groups for 10 days receivedeither i) E2 (0.017 mg/day, n=12) ii) E2 plus angiogenesis inhibitor TNP-470
(1.2 mg/day, n=3) iii) ERb-agonist DPN(0.34 mg/day, n=3) iv) ERa-agonist
PPT(0.34mg/day, n=3) or v) left untreated(RVF, n=7). Saline-treated rats served
as controls(CTRL, n=6). Echocardiography, cardiac catheterization, RT-PCR,
Western-blot and immunocytochemistry were performed. MCT-group devel-
oped severe PH at day21 as RV-pressure (RVP) increased from 3152 in
CTRL to 6952 mmHg. E2 reversed PH(RVP=3852mmHg, P<0.05) com-
pletely resulting in full recovery. Interestingly, E2 failed to rescue PH when ap-
plied together with TNP. VGEF protein in RV and lungs was reduced
significantly ~5fold in PH and E2 increased VEGF significantly ~10 fold. Re-
duced RV capillary-density in PH was restored fully by E2. E2 reduced cardio-
pulmonary inflammation as IL-6 transcript upregulation in PH(~22 fold in lung,
~7 folds in RV) was partially reversed by E2. Lungs showed 4-fold increase in
ED1-inflammatory cells in PH and E2 reversed this increase. Lung ERb-
transcripts, but not ERa, were significantly reduced 6-fold in PH and were re-
stored by E2. ERb protein in lung and RV was also significantly reduced ~2
fold in PH and E2 restored ERb. ERb agonist DPN was as effective as E2 to res-
cue PH (RVP=3451 mmHg), whereas PPT was not as effective. In conclusion,
E2 rescues PH by stimulating cardiopulmonary neoangiogenesis and suppress-
ing inflammation mainly via ERb.
2277-Pos Board B263
Expression and Spectroscopic Characterization of Melanopsin and Squid
Rhodopsin
Nazhat Shirzad-Wasei, Erica Saint Clair, John I. Ogren, Christie Stanzel,
Javier Navarro, Willem J. deGrip, Kenneth J. Rothschild.
Melanopsin, found in intrinsically photosensitive retinal ganglion cells, drives
circadian rhythm and pupillary response. A variety of studies indicate that mel-
anopsin shares many properties with invertebrate rhodopsin such as found in
the eyes of squid including activation by an initial photon absorption and regen-
eration to the original state with a second red-shifted photon. We report the ex-
pression and initial spectroscopic characterization of recombinant expressed
melanopsin. Mouse melanopsin, carrying a C-terminal deca-his-tag, was ex-
pressed in Sf9 insect cells, using recombinant baculovrius. Good expression
levels of intact melanopsin protein were achieved (2-4 mg/l). To regenerate
the active photopigment 11-cis retinal was added. However, solubilization ef-
ficiency was quite low for most detergents. Best results were obtained with do-
decylphosphocholine (DPC). Efficient single-step purification was achieved
with affinity chromatography over immobilized Ni-2þ ions. So far only a small
percentage of the purified melanopsin was photoactive, showing a maximum
absorbance at 480-500 nm. Preliminary low-temperature FTIR difference and
resonance Raman spectroscopic measurements are reported for melanopsin
and squid rhodopsin in order to compare structural features and conformational
changes upon light activation including retinal isomerization and protein back-
bone changes. Supported by a grants from the NIH-NEI to KJR and from
NWO-CW to WJdG.
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FGF13 is a Regulator of the Cardiac Voltage-Gated Sodium Channel
Nav1.5
Chuan Wang, Jessica A. Hennessey, Robert D. Kirkton, Chaojian Wang,
Victoria Bryson, Paul B. Rosenberg, Nenad Bursac, Geoffrey S. Pitt.
The four members of the intracellular Fibroblast Growth Factor (iFGF) subfam-
ily, FGF11-14, regulate voltage-gated sodium (Nav) channels. Amissense muta-
tion in FGF14 causes spinocerebellar ataxia 27, thought to be due to Nav channel
dysfunction. iFGFs are expressed in the heart, but whether they regulate cardiac
Nav channels is not known. Using quantitative real-time RT-PCR, we identified
that FGF13 isoforms are the dominant iFGFs in adult mouse heart. Using whole
cell patch-clamp configuration, we determined a functional link between FGF13
and Nav1.5. We found that the FGF13 isoforms, FGF13S, FGF13U, and
FGF13VY differentially modulate Nav1.5 current density when transiently co-
expressed in HEK293 cells. Steady-state activation was not altered. In contrast,
steady-state availability was significantly shifted towards the depolarizing direc-
tion by each of the FGF13 isoforms.Most strikingly, FGF13S induced a dramatic
slowing of recovery from inactivation. Co-immunoprecipitation showed that
FGF13 interacted with Nav1.5 in cardiomyocytes. Using a pull down assay,
we found that FGF13 directly interacted with C-terminus of Nav1.5. Immunos-
taining showed that FGF13 co-localized with Nav1.5 on sarcolemma. Some
FGF13 is present in subcellular regions devoid of Nav1.5, suggesting other roles
than sodium channel modulation. FGF13 knockdown by adenoviral infection
with shRNA in adult mice cardiomyocytes affected sodium current density and
steady-state availability. FGF13 knockdown in a neonatal rat cardiomyocyte
monolayer reduced cardiac impulse conduction and the velocity of the action
Tuesday, March 8, 2011 421apotential upstroke. These data are the first report of FGF13 as regulator ofNav1.5
in heart and suggest that FGF13 isoform-specific regulation of cardiac Nav chan-
nels plays important physiological and pathophysiological roles.
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CaMKII Regulates Cardiac Sodium Channel Nav1.5 by Phosphorylation
in the Loop Between Domain I and II
Anthony W. Herren, Nicole M. Ashpole, Kenneth S. Ginsburg,
Donald M. Bers, Andy Hudmon.
The cardiac Na channel NaV1.5 current (INa) is critical to cardiac excitability
and altered INa gating has been implicated in genetic and acquired arrhyth-
mias. Ca-calmodulin dependent protein kinase (CaMKII) is upregulated in
heart failure and has been shown to cause INa gating changes that mimic
a point mutant in humans associated with combined long QT and Brugada
syndromes. We sought to identify the CaMKII phosphorylation target site
on NaV1.5 that mediates the CaMKII-induced alterations in INa gating. We an-
alyzed CaMKII-dependent phosphorylation of NaV1.5 intracellularly accessi-
ble sites using a series of GST-fusion constructs, immobilized peptide arrays,
and soluble peptides. CaMKII phosphorylation sites were identified at S516
and S593/T594 in the intracellular NaV1.5 loop between domains 1 and 2.
Wild-type (WT) and phospho-mutant human Nav1.5 were co-expressed
with CaMKIIdC-GFP in HEK293 cells and INa was recorded by whole-cell
patch clamp under pipette conditions that acutely activated CaMKII (þ1
mM free [Ca], þ 1 mM Calmodulin). As observed in myocytes, CaMKII
shifted WT INa availability to more negative membrane potentials and en-
hanced accumulation of INa into intermediate inactivation, but these effects
were abolished by mutating either of the CaMKII sites to non-
phosphorylatable alanine residues (V1/2 of availability: WT 101.8 5 4.5
(n=10); S593/T594AA 89.7 5 3.5 (n=11) ; S516A 93.0 5 5.5 (n=18)).
Furthermore, the phospho-mutant channels mimicked WT INa treated with 1
mM AIP, a specific CaMKII inhibitor, and AIP had no effect on phospho-
mutant INa. CaMKII activation had no effect on the V1/2 of activation or I-
V curve shape of any channel. CaMKII-dependent phosphorylation of
NaV1.5 at multiple sites (including Ser593/Thr594 and Ser516) appears to
be required to evoke loss-of-function changes in gating that could contribute
to acquired Brugada syndrome like effects in heart failure.
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Chlorobutanol, a Pharmaceutical Preservative and Sedative Hypnotic,
Inhibits Brain Type Voltage Gated Sodium Channels
George Kracke, Alice Landrum.
Introduction- Chlorobutanol (1,1,1-trichloro-2-methyl-2-propanol) is a widely
used chemical preservative for injectabledrugs, eyedrops,mouthwashes, and cos-
metics. It is ananalgesic, experimental general anesthetic, and sedativehypnotic in
man. The mechanism of action of chlorobutanol is unclear. Our goal was to test
whether chlorobutanol inhibits brain type voltage gated sodium channels.
Methods- Mammalian Nav 1.2 voltage gated sodium channels were expressed
in Xenopus oocytes by injecting the alpha subunit cRNA. Inward sodium cur-
rents were measured with two-electrode voltage clamp using standard depolar-
ization protocols. The study was approved by our institutional animal care and
use committee.
Results- Chlorobutanol was tested at concentrations ranging from 0.03 to 10
mM. Chlorobutanol reversibly inhibited closed, resting channels and inacti-
vated channels in a concentration dependent manner. The voltage dependence
of activation was shifted in the depolarizing direction. Fast inactivation voltage
dependence was not affected. There was little state dependent block and no ap-
parent use dependence.
Discussion and Conclusions- Chlorobutanol inhibited Nav 1.2 channels at con-
centrations less than those used to preserve pharmaceuticals. Its use as a preser-
vative in injectable methadone and local anesthetic solutions, and in eye drops
likely adds an analgesic component to these solutions.
2281-Pos Board B267
Enhancement of Slow Inactivation of Voltage-Gated Naþ Channels by
Ranolazine
Ryoko Hirakawa, Lynda V. Liu, John C. Shryock, Luiz Belardinelli,
Sridharan Rajamani.
Ranolazine is an anti-anginal drug that blocks cardiac (Nav1.5) late Na
þ current
(INa) at therapeutic concentrations (2-10 mM). Recent electrophysiological
studies have shown that ranolazine also blocks skeletal muscle (Nav1.4) and
neuronal (Nav1.1, Nav1.7, Nav1.8) INa. We investigated the effects of ranola-
zine on peak INa and on both sustained repetitive firing (SRF) and 0 mM
Mg2þ- induced (0 [Mg2þ]O) continuous high frequency firing of action poten-
tials in cultured rat hippocampal neurons. Ranolazine caused a voltage (60
mV) and frequency (10 Hz)-dependent inhibition of INa with IC50 values of0.48 and 61.8 mM (n=4-6), respectively.
Ranolazine (10 mM, n=4) did not shift
the voltage-dependence of steady-state
fast inactivation; however, it caused
a 15-mV hyperpolarizing shift
(p<0.05, compared to control, n=4) in
the slow inactivation. Consistently, ra-
nolazine (10 mM) reduced SRF only
during a 4-sec burst but not with a 1-
sec depolarization step (Fig.1). Further-
more, ranolazine (10 mM) reduced
0 [Mg2þ]O -induced high frequency fir-
ing of spontaneous action potentials
from 0.78 to 0.45 Hz (p<0.05, n=5). Taken together, these data suggest that ra-
nolazine suppresses the propagation and conduction of action potentials by
preferentially interacting with Naþ channels in the slow inactivated state.
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Y1767C, a Novel SCN5A Mutation Induces a Persistent Sodium Current
and Potentiates Ranolazine Inhibition of NaV1.5 Channels
Hai Huang, Silvia G. Priori, Carlo Napolitano, Michael E. O’Leary,
Mohamed Chahine.
LongQT syndrome type 3 (LQT3) has been traced tomutations of the cardiacNa
channel (Nav1.5) that produce persistent Na currents leading to delayed ventric-
ular repolarization and Torsades de pointes. We performed mutational analyses
of patients suffering from LQTS and characterized the biophysical properties of
the mutations that we uncovered. One LQT3 patient carried a mutation in the
SCN5A gene in which the cysteine was substituted for a highly conserved tyro-
sine (Y1767C) located near cytoplasmic entrance of the Nav1.5 channel pore.
The wild-type and mutant channels were transiently expressed in tsA201 cells,
and the Na currents were recorded using the patch-clamp technique. The
Y1767C channel produced a persistent Na current, more rapid inactivation,
faster recovery from inactivation, and an increased window current. The persis-
tent Na current of the Y1767C channel was blocked by ranolazine but not by
many class I antiarrhythmic drugs. The incomplete inactivation, along with
the persistent activation of Na channels caused by an overlap of voltage-
dependent activation and inactivation, known as window currents, appeared to
contribute to the LQTS phenotype in this patient. The blocking effect of ranola-
zine on the persistent Na current suggested that ranolazine may be an effective
therapeutic for treating patients with this mutation. Our data also revealed the
unique role for the Y1767 residue in inactivating and forming the intracellular
pore of the Nav1.5 Na channel.
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The Selective Nav1.8 Sodium Channel Blocker A-803467 Affects Electrical
Activity in Intracardiac Neurons, but not in Cardiomyocytes
Marieke W. Veldkamp, Carol A. Remme, Brendon Scicluna,
Cees A. Schumacher, Rianne Wolswinkel, Antoni C.G. van Ginneken,
Connie R. Bezzina, Arie O. Verkerk.
Background. Recently we observed differential myocardial expression of the
brain-type sodium channel isoform Scn10a between two inbred mouse strains,
both harboring the Scn5a-1798insDþ/- mutation and displaying different se-
verity of conduction disease. The functional role of Scn10a in the heart is as
yet unknown, and we therefore investigated expression and channel activity
of NaV1.8 (encoded by Scn10a) in intracardiac neurons and myocardium of
the murine heart.
Methods. Immunocytochemistry was performed using anti-NaV1.8 antibody
on mouse embryos and adult murine cardiac tissue sections. The effect of the
NaV1.8 blocker A-803467 (500 nM) on action potentials (AP’s) and sodium
current (INa) properties was assessed in isolated intracardiac neurons and ven-
tricular myocytes.
Results. In embryonic and adult heart tissue sections, NaV1.8 staining was ob-
served at the epicardial surface, and within the myocardium in between cardio-
myocytes. The NaV1.8 blocker A-803467 had no effect on either mean INa
density or INa kinetic properties in isolated myocytes, but clearly reduced INa
density in intracardiac neurons (344551 pA/pF versus control 448561;
mean5SEM, n=11). In addition, the slow component of the current decay (tslow)
at20mVwas accelerated in thepresence ofA-803467 (2.850.3msversus con-
trol 3.450.4 ms; mean5SEM, n=5) and V1/2 of voltage-dependent inactivation
was shifted by 9.6 mV (73.652.0 mV versus control 64.051.6 mV;
mean5SEM, n=5). This is consistent with a reduction in slowly inactivating
brain-type sodium current with depolarized voltage-dependent inactivation. In
AP measurements A-803467 did not affect cardiomyocyte upstroke velocity,
but reduced AP firing frequency in intracardiac neurons by 50%.
